drugset / Trial / NCT02134808
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP) concentrations. A secondary hypothesis is that decreased depressive symptoms measured with the Children's Depression Rating Scale-Revised (CDRS-R) and Montgomery-Asberg Depression Rating Scale (MADRS) will be reciprocally correlated with increased β-NTP concentrations.
Timeline
- Start
- 2014-11-21
- Primary completion
- 2017-06-27
- Completion
- 2017-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Creatine | Other / unclassified | 10 g | — |